00:56 , Mar 29, 2017 |  BC Week In Review  |  Clinical News

CM-24: Ph I terminated

Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of efficacy in the trial and that...
19:44 , Mar 23, 2017 |  BC Extra  |  Clinical News

Merck ends development of cCAM compound

Merck & Co. Inc. (NYSE:MRK) terminated development of oncology candidate CM-24 , spokesperson Pamela Eisele told BioCentury. Eisele said the mAb showed no signs of efficacy in a dose-ranging Phase I study in combination with...
07:00 , May 30, 2016 |  BioCentury  |  Finance

Re-upping in Israel

OrbiMed Advisors is coming back for seconds in Israel with a $307 million fund focused on the country. This time, the Israeli government is not providing a safety net, but many of the original LPs...
01:39 , Jan 13, 2016 |  BC Extra  |  Company News

Merck acquires IOmet

Merck & Co. Inc. (NYSE:MRK) acquired IOmet Pharma Ltd. (Edinburgh, U.K.), gaining the biotech's preclinical pipeline of inhibitors of indoleamine 2,3-dioxygenase 1 ( IDO1 ) and tryptophan 2,3-dioxygenase ( TDO2 ; TDO ) as well...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

cCAM Biotherapeutics, Merck deal

Merck will acquire cCAM for $95 million in cash plus up to $510 million in undisclosed development, regulatory and commercial milestones. Merck gains CM-24 , a humanized IgG4 mAb targeting carcinoembryonic antigen (CEA)-related cell adhesion...
01:44 , Jul 29, 2015 |  BC Extra  |  Company News

Merck to acquire cCAM

Merck & Co. Inc. (NYSE:MRK) will acquire cancer immunotherapy play cCAM Biotherapeutics Ltd. (Misgav, Israel) in a deal worth up to $605 million. The acquisition gives Merck lead candidate CM-24 , a humanized IgG4 mAb...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

CM-24: Phase I started

cCam began an open-label, dose-escalation, international Phase I trial to evaluate IV CM-24 in about 62 patients with advanced or recurrent malignancies, including melanoma and bladder, colorectal, gastric, ovarian and non-small cell lung cancers (NSCLC)....
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
08:00 , Jan 29, 2015 |  BC Innovations  |  Product R&D

Company checkpoints

The spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of...
00:23 , Sep 15, 2012 |  BC Extra  |  Financial News

Israeli cancer company cCAM debuts with A round

Cancer immunotherapy company cCAM Biotherapeutics Ltd. (Kiryat-Shmona, Israel) raised an undisclosed amount in a series A round led by Arkin Holdings. OrbiMed Israel Partners; Pontifax; and Roche (SIX:ROG; OTCQX:RHHBY) participated. cCAM's CM-10 , a humanized...